Chemicals & Small Molecules

Huwentoxin-IV (Legacy Tebubio ref. 282TP2016). Selective NaV1.7 channel blocker. Preferentially inhibits neuronal NaV1.7, 1.2 and 1.3 (IC50 values are 26, 150 and 338 nM respectively), compared to muscle subtypes NaV1.4 and 1.5 (IC50 = >10 μM). Inhibits the channel by binding at the neurotoxin receptor site 4 in the S3-S4 linker of domain II, trapping the voltage sensor in the inward, closed configuration.

GIP (1-39) (Legacy Tebubio ref. 282TP2017). Endogenous truncated form of the incretin hormone GIP. More potent at stimulating glucose-dependent insulin secretion from rat pancreatic β-cells than GIP.

GIP (1-39) acetate (Legacy Tebubio ref. 282TP2017L). GIP (1-39) acetate is a gastric inhibitory peptide (GIP) purified from porcine intestine and stimulates insulin secretion.

GIP, human (Legacy Tebubio ref. 282TP2018). Potent insulinotropic hormone synthesized by duodenal K-cells. High affinity GIP receptor agonist (EC50 = 0.81 nM) that inhibits gastric acid secretion and stimulates pancreatic insulin release in response to glucose. Also affects lipid metabolism and displays mitogenic and antiapoptotic effects in pancreatic β-cells.

GIP (human) acetate (Legacy Tebubio ref. 282TP2018L). GIP (human) acetate is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP (human) acetate plays a vital role in lipid metabolism and the development of obesity.

[D-Ala2]-GIP (human) (Legacy Tebubio ref. 282TP2019). Highly potent GIP receptor agonist (EC50 = 630 ± 119 pM). Displays equivalent cAMP stimulating properties and improved resistance to enzymatic degradation compared to native GIP in cells expressing wild type GIP receptor. Improves glucose tolerance, insulin release and cognitive function in various animal models of obesity and diabetes. Displays neuroprotective effects in an MPTP model of PD.

[Pro3]-GIP (Mouse) (Legacy Tebubio ref. 282TP2020). GIP receptor antagonist (IC50 = 2.6μM). Inhibits GIP-stimulated insulin release from pancreatic β cells in vitro. In ob/ob mice, blocks the effects of GIP on insulin release and plasma glucose levels. Also improves intraperitoneal glucose tolerance, insulin sensitivity, and glucose response to feeding in ob/ob mice.

[Pro3]-GIP (Mouse) acetate (Legacy Tebubio ref. 282TP2020L). [Pro3]-GIP (Mouse) acetate is mouse [Pro3]-GIP. [Pro3]-GIP is a GIP receptor antagonist.

[Pro3]-GIP (Rat) (Legacy Tebubio ref. 282TP2021). High affinity rat GIP receptor partial agonist (Kd = 13 nM). Increases cAMP accumulation in COS-7 cells transfected with rat GIP receptor, while also acting as a competitive antagonist of GIP.